FGFR4 and neoplasm: These ADCs may provide a selective approach to delivering cytotoxic agents specifically to FGFR4-positive tumor cells, thereby reducing off-target toxicity and offering a promising immunotherapeutic strategy for the treatment of RMS, HCC, and BC.